Skip to content

Dexmedetomidine Combined with Esketamine for Improving Postoperative Sleep Disturbance After Total Hip Arthroplasty

Dexmedetomidine Combined with Esketamine for Improving Postoperative Sleep Disturbance After Total Hip Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117825
Enrollment
Unknown
Registered
2026-01-29
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Sleep Disturbances,PSD

Interventions

E Group:Intraoperatively, patients received a continuous infusion of esketamine at 0.2 mg/kg/h with a concomitant, volume-matched infusion of normal saline.
D Group:Intraoperatively, patients received a continuous infusion of dexmedetomidine at 0.2 µg/kg/h with a concomitant, volume-matched infusion of normal saline.
DE Group:Intraoperatively, patients received a continuous infusion of dexmedetomidine at 0.2 µg/kg/h in combination with esketamine at 0.2 mg/kg/h.

Sponsors

The Second Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective total hip arthroplasty; 2. Aged between 60 and 80 years; 3. BMI between 18 and 30 kg/m²; 4. No severe preoperative sleep disturbance (defined as PSQI <= 11); 5. American Society of Anesthesiologists (ASA) physical status class I–III; 6. Informed consent form signed by the patient or legal representative.

Exclusion criteria

Exclusion criteria: 1. Allergy to the investigational drug(s); 2. Use of sedatives, antidepressants, or hypnotics within one month prior to surgery; 3. Sick sinus syndrome, type II second-degree or third-degree atrioventricular block; sinus bradycardia; uncontrolled hypertension (systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mmHg); 4. Diagnosed sleep apnea syndrome; 5. History of abnormal surgical or anesthetic recovery; 6. Severe psychiatric disorder, cognitive dysfunction, or speech/hearing/visual impairment that hinders assessment; 7. Comorbid severe cardiac or pulmonary insufficiency, severe hepatic insufficiency, severe renal insufficiency, etc.; 8. Participation in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Subjective sleep quality score on the first postoperative night;

Secondary

MeasureTime frame
Subjective sleep quality scores on the night before surgery, the second, and third postoperative nights;Pittsburgh Sleep Quality Index score at 1 month postoperatively;Postoperative pain score;Postoperative adverse events;Postoperative anxiety and depression scores;

Countries

China

Contacts

Public ContactMingjian Kong

The Second Affiliated Hospital of Xuzhou Medical University(Xuzhou Mining Group General Hospital)

mjkong@126.com+86 177 5199 1669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026